secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001493152-24-028343
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient
--------------------------------------------------------------------------------

- PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).
- Patient had failed 8 prior regimens including ADC therapy; continues on BriaCell treatment.
- Brain lesion undetectable, orbital lesion shrinking; tumor markers markedly decreased from pre-treatment.
- Phase 2 study of Bria-IMT regimen plus immune checkpoint inhibitor in metastatic breast cancer.
- Patient remains alive; company plans to replicate results in ongoing Phase 3 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224028343/0001493152-24-028343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224028343/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer